Commercial Excellence 
Our recent webinar, “The Shifting Landscape of Account Management in Pharma: Navigating Specialty and Rare Disease in Integrated Networks” explored the critical evolution of the pharmaceutical industry’s portfolio towards Specialty and rare disease medications, the impact on our customers, and the subsequent need to incorporate a strategic account management approach to succeed in this marketplace. This article expands on the key themes and insights shared during the session.
The healthcare landscape continues to undergo dramatic transformation as health systems and payers increasingly centralize their decision-making processes. Individual physician autonomy in treatment choices has given way to committee-based protocols and pathways. This fundamental shift requires life sciences companies to radically rethink their customer engagement approaches to remain effective in this new environment.
The New Decision-Making Reality
Traditional life sciences sales models focused primarily on individual physician relationships and clinical messaging. However, today’s reality is far more complex. Key decisions about product access, protocol inclusion, and formulary position are increasingly made by cross-functional committees at regional and system levels. These committees typically include clinical, administrative, and financial stakeholders – each bringing different priorities and perspectives to the decision process.
For example, a major academic medical center recently restructured its evaluation process for Specialty products. Rather than leaving choices to individual departments, all new therapies must now go through a value analysis committee that considers clinical evidence, total cost of care impact, and operational implications. Similar shifts are occurring across healthcare as organizations seek to standardize care delivery while optimizing outcomes and costs.
Implications for Customer Engagement
This evolution in decision-making requires a corresponding evolution in engagement strategy. Organizations must move beyond traditional representative-driven models to deploy sophisticated account teams capable of engaging multiple stakeholders. These teams need a deep understanding of system priorities, decision processes, and value drivers at both institutional and individual levels.
Success requires careful orchestration of engagement across functions. Medical teams must effectively communicate scientific evidence to clinical leaders. Market access specialists need to articulate economic value propositions to financial stakeholders. Account managers must coordinate these interactions while maintaining strategic relationships with key decision makers.
The timeline for engagement has also shifted dramatically. Rather than focusing on near-term prescribing decisions, organizations must now plan for extended evaluation and implementation cycles. Building consensus across stakeholder groups requires sustained, coordinated effort over months or even years.
Mastering the engagement approach
This sort of approach requires Strategic Account Management which demands sophisticated capabilities across several dimensions. First is stakeholder mapping – understanding who influences decisions, their individual priorities, and their relationships with each other. This insight allows teams to develop targeted engagement strategies for each key stakeholder while maintaining coordination across interactions.
Teams must also become adept at articulating differentiated value propositions for various stakeholders. Clinical value for physicians, economic value for administrators, and operational value for implementation teams all need clear articulation. More importantly, these various value elements must align into a compelling overall narrative that drives consensus.
Success also requires careful attention to process and timing. Teams need to understand formal and informal decision processes, identify key milestones, and sequence interactions appropriately. Building internal champions who can advocate effectively during committee discussions is particularly critical.
The Path Forward
The shift toward centralized, committee-based decision making shows no signs of slowing. Life sciences companies must continue evolving their engagement models to succeed in this new environment. This requires sustained investment in building strategic account team capabilities, developing sophisticated engagement tools and resources, and fostering cultures that support coordinated customer interaction.
Organizations that master this approach position themselves to create compelling value propositions that resonate across stakeholder groups, especially in the Specialty and rare disease marketplaces. Those that remain focused on traditional engagement models risk finding themselves increasingly marginalized in key account decisions. With the future evolving to a more heavily weighted focus on Specialty and rare disease products, companies that can effectively orchestrate cross-functional engagement as part of a strategic account management approach will have a competitive advantage.
Next Steps
At WLH, we are experts in transforming strategic account management capabilities for life sciences organizations. As the industry landscape rapidly evolves, we can help you future-proof your SAM function.
Our team can provide a comprehensive assessment of your current abilities, identify strategic gaps, and co-create a customized roadmap for building world-class account management competencies.
To discuss your specific needs and challenges, please reach out to schedule a complimentary consultation. We’re confident we can help you navigate the shifting tides of Specialty and rare disease account management and deliver meaningful value for your critical healthcare partners.
